Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates
May 5, 2015 4:00 PM EDTMarketing Submissions for Migalastat Monotherapy for Fabry Disease on Track for 2Q15 in Europe and 2H15 in United States Net Cash Spend Guidance Updated to $100-$110 Million on Accelerated Commercialization and Manufacturing Next-Generation Pompe ERT Set to Enter Clinic in 2H15
CRANBURY, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March... More
